

SCYNEXIS Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 26-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

 Phase 2 Clinical..... 12

 Phase 1 Clinical..... 21

 Discovery..... 28

 Suspended..... 44

[Return to Table of Contents](#)

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | SCYNEXIS Inc |
| Parent Company Name | SCYNEXIS Inc |
| Website | http://www.scynexis.com/ |
| Country | US |
| Number of Drugs in Active Development | 8 |
| Number of Inactive Drugs | 7 |
| Number of Patents as Owner | 21 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 24 |
| Key Indications | Fungal infection, Trypanosoma cruzi infection, Trypanosoma brucei infection, Candida infection, Leishmania donovani infection, Parasitic infection, Hepatitis C virus infection, HIV infection, Alzheimers disease, Amoeba infection, Aspergillus infection, Asthma, Autoimmune disease, Cryptococcus infection, Dengue virus infection, Glomerulonephritis, Hepatitis B virus infection, Influenza virus infection, Insulin dependent diabetes, Ischemia, Keratitis, Meningitis, Pneumonia, Psoriasis, Reperfusion injury, Respiratory syncytial virus infection, Toxoplasma infection, Trichomonas |
| Key Target-based Actions | Peptidylprolyl isomerase inhibitor, 1,3 beta glucan synthase inhibitor, Calcineurin inhibitor, Peptidyl-prolyl cis-trans isomerase D inhibitor, Glucan synthase inhibitor, IL-2 antagonist, Interleukin-29 ligand |
| Key Technologies | Small molecule therapeutic, Biological therapeutic, Oral formulation, Peptide, Capsule formulation, Intravenous formulation, Natural product, Assay, Chemical isolation, Fermentation synthesis, Stereochemical |

COMPANY PROFILE

SUMMARY

SCYNEXIS (formerly SCYNEXIS Chemistry & Automation) is a chemistry- focused drug discovery company. Formed in 2000 as an independent spin-off of Aventis CropScience, SCYNEXIS utilizes its proprietary MEDCHEM-FACTORY to optimize lead molecules for candidate selection and deliver drug pipeline solutions to pharmaceutical partners from early discovery to phase II.

COMPANY LOCATION

In December 2009, the company's process chemistry, analytical and manufacturing facilities were found to be in full compliance with cGMP manufacturing and analytical regulations following an FDA inspection.

LICENSING AGREEMENTS

In May 2009, SCYNEXIS granted Medicines for Malaria Venture (MMV) access to its HEOS drug discovery platform.

In December 2008, SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi) extended their research alliance for an added three years. In November 2007, SCYNEXIS and DNDi established a drug research alliance to discover therapies for sleeping sickness.

In December 2006, SCYNEXIS Chemistry & Automation and Merck & Co formed a multi-year research collaboration to discover and develop new cancer drugs. SCYNEXIS would produce highly-targeted compound libraries and use rapid lead optimization techniques to select drug candidates. In October 2009, SCYNEXIS received a payment for a preclinical milestone.

By December 2005, SCYNEXIS and Merial were collaborating on the research of novel compounds for animal health needs. In November 2009, SCYNEXIS received a milestone payment from Merial in its multi-year research collaboration.

[Return to Table of Contents](#)



In October 2005, SCYNEXIS agreed to provide medicinal and analytical chemistry services for Teijin Pharma's drug development programs.

In April 2004, Norak Biosciences Inc and SCYNEXIS entered into a R&D collaboration. Norak transferred certain active compounds and chemical structures from its Transfluor screening program against novel desensitization targets to SCYNEXIS. Norak was to gain access to a SCYNEXIS research unit, which included medicinal chemistry technology and expertise. Norak was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services.

In November 2002, SCYNEXIS entered into a research collaboration with F Hoffmann-La Roche Ltd to discover and develop novel compounds for the CNS, and metabolic diseases. The transaction would include access by Roche to the SCYNEXIS MEDCHEM-FACTORY technology and HEOS Hit Explorer Operating System software, thus accelerating the identification of novel leads against Roche's drug targets by producing large, focused, high-purity compound libraries and then utilizing rapid lead optimization to identify clinical candidates. Specific financial terms were not disclosed. However, Roche was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services. In September 2003, this collaboration was extended.

In June 2002, SCYNEXIS entered into a multiyear research collaboration with Merck & Co Inc to discover and develop novel anti-infective compounds. Utilizing its proprietary MEDCHEM-FACTORY technology, SCYNEXIS was to accelerate the identification of novel drugs against Merck's screening targets by producing large, highly targeted, high-purity compound libraries. Merck was to receive exclusive worldwide rights to products developed through the collaboration. SCYNEXIS was to receive milestone payments and royalties on sales. In July 2003, this research collaboration was expanded. In January 2007, SCYNEXIS received a \$1 million payment from Merck & Co for meeting preclinical milestones under the companies' 2002 collaboration to develop antifungal agents. In December 2009, SCYNEXIS achieved a third milestone in its collaboration with Merck & Co to develop antifungals. The milestone was triggered by the initiation of clinical development for a compound generated under the collaboration. Under the terms of the original agreement, SCYNEXIS would receive milestones and double-digit percentage royalties.

In December 2001, Plexxikon Inc signed an agreement with SCYNEXIS, under the terms of which Plexxikon will access SCYNEXIS' proprietary MEDCHEM-FACTORY technology in order to accelerate its chemistry programs.

In February 2001, SCYNEXIS formed an alliance with two additional specialized research companies, Piedmont Research Center and Biotechnics Inc, to enhance its ability to quickly identify and bring forward the development of promising drug candidates.

FINANCIAL

In April 2015, the company initiated an underwritten public offering of shares of its common stock to raise a gross proceeds of up to \$30 million. At that time, a 30-day option was granted to the underwriters for the purchase of an additional \$4.5 million of shares. Later that month, the company priced the offering of 4,675,324 shares at \$7.70 per share, with underwriters granted a 30-day option to purchase up to 701,298 additional shares.

By June 2014, SCYNEXIS had repayed a \$15 million credit facility.

In May 2014, the company priced its IPO of 6,200,000 shares of its common stock at \$10 per share. The underwriters were also granted a 30-day over-allotment option to purchase up to an additional 930,000 shares of common stock. In June 2014, the company raised net proceeds of \$40 million from the completed offering.

In March 2014, the company announced a initial public offering of 4,230,800 shares of its common stock priced between \$12.00 and \$14.00 per share. The underwriters were to be granted a 30-day option to purchase additional 634,620 shares of the common stock. At that time, the company filed an application to list the shares under the ticker symbol "SCYX" on the NASDAQ Global Market. In May 2014, the company's shares began trading on the NASDAQ Global Market.

In March 2008, SCYNEXIS completed a \$13.5 million Series C2 financing.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|--------------------------|--------|----------|-------|
| Infectious disease | 8 | 5 | 13 |
| Inflammatory disease | 0 | 5 | 5 |
| Gastrointestinal disease | 0 | 4 | 4 |
| Cardiovascular disease | 0 | 1 | 1 |
| Metabolic disorder | 0 | 1 | 1 |
| Neurological disease | 0 | 1 | 1 |
| Injury | 0 | 1 | 1 |
| Musculoskeletal disease | 0 | 1 | 1 |
| Endocrine disease | 0 | 1 | 1 |
| Ocular disease | 0 | 1 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 2 Clinical | 1 |
| Discovery | 6 |
| Suspended | 1 |
| Discontinued | 1 |
| No Development Reported | 6 |

[Return to Table of Contents](#)

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Discovery/Design | 3 | 0 | 1 | 0 | 4 |
| Technology - Other Proprietary | 5 | 0 | 0 | 0 | 5 |
| Drug - Funding | 2 | 0 | 0 | 0 | 2 |
| Drug - Early Research/Development | 1 | 0 | 2 | 0 | 3 |
| Drug - Development/Commercialization License | 3 | 0 | 0 | 0 | 3 |
| Drug - Development Services | 6 | 0 | 0 | 0 | 6 |
| Technology - Target Validation | 0 | 1 | 0 | 1 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|--------------------------|---------|-----|
| Infectious disease | 1 | 4 |
| Gastrointestinal disease | 0 | 3 |
| Inflammatory disease | 0 | 3 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 1 | 2 |
| Phase 1 | 0 | 2 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|------------------------|----------|----------------|-------|
| Cardiovascular disease | 1 | 0 | 1 |
| Endocrine disease | 1 | 0 | 1 |

[Return to Table of Contents](#)



| | | | |
|--------------------------|----|---|----|
| Gastrointestinal disease | 13 | 0 | 13 |
| Genitourinary disease | 1 | 0 | 1 |
| Degeneration | 1 | 0 | 1 |
| Immune disorder | 1 | 0 | 1 |
| Ocular disease | 2 | 0 | 2 |
| Metabolic disorder | 1 | 0 | 1 |
| Neurological disease | 2 | 0 | 2 |
| Respiratory disease | 3 | 0 | 3 |
| Infectious disease | 21 | 0 | 21 |
| Injury | 1 | 0 | 1 |
| Inflammatory disease | 16 | 0 | 16 |
| Dermatological disease | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

SCY-078

SCY-078 SNAPSHOT

| | |
|----------------------|---|
| Drug Name | SCY-078 |
| Key Synonyms | |
| Originator Company | Merck & Co Inc |
| Active Companies | R-Pharm;SCYNEXIS Inc |
| Inactive Companies | Merck & Co Inc |
| Highest Status | Phase 2 Clinical |
| Active Indications | Candida infection;Fungal infection |
| Target-based Actions | 1,3 beta glucan synthase inhibitor |
| Other Actions | Glucan synthesis inhibitor;Fungicide |
| Technologies | Natural product;Oral formulation;Small molecule therapeutic |
| Last Change Date | 23-Apr-2015 |

SCY-078 DEVELOPMENT PROFILE

SUMMARY

SCYNEXIS and R-Pharm, formerly in collaboration with Merck, are developing SCY-078 (formerly MK-3118; structure shown), the lead from analogs of enfumafungin, a triterpene glycoside derived from a culture belonging to the genus *Hormonema*, as beta-(1,3) D glucan synthase inhibitors for the potential oral treatment of fungal infections, including invasive candidiasis,,.

In September 2014, a phase II trial was initiated in the US in hospitalized non-neutropenic adults with invasive candidiasis ; in March 2015, topline results from the trial were expected in the first half of 2016.

Merck & Co was previously developing the drug in collaboration with SCYNEXIS . However in May 2013, following a review and prioritization of Merck's infectious disease pipeline, rights were returned to SCYNEXIS.

SCYNEXIS is also investigating intravenous formulations of SCY-078.

SCY-078 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS


| Company | Indication | Country | Development Status | Date |
|---------|------------|---------|--------------------|------|
|---------|------------|---------|--------------------|------|


[Return to Table of Contents](#)




| Company | Indication | Country | Development Status | Date |
|----------------|-------------------|--------------------|--------------------|-------------|
| SCYNEXIS Inc | Candida infection | US | Phase 2 Clinical | 27-Sep-2014 |
| SCYNEXIS Inc | Fungal infection | US | Phase 1 Clinical | 31-Oct-2009 |
| R-Pharm | Fungal infection | Russian Federation | Discovery | 10-Sep-2013 |
| Merck & Co Inc | Fungal infection | US | Discontinued | 29-May-2013 |


SCY-078 CHEMICAL STRUCTURES


| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| | 4 |
|  | |
| Name | Type |
| SCY-078 | Research Code |
| MK-3118 | Research Code |

| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| | 3 |
|  | |
| Name | Type |
| enfumafungin | |


[Return to Table of Contents](#)


| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |

| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |

[Return to Table of Contents](#)

| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |




| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |

SCY-078 DRUG NAMES

| Names | Type |
|--|---------------|
| MK-3118 | Research Code |
| antifungal compounds (1,3 beta glucan synthase inhibitors), Merck/SCYNEXIS | |
| SCY-078 | Research Code |
| enfumafungin analogs (antifungal), Merck & Co/SCYNEXIS | |
| enfumafungin | |
| triterpene glycoside analogs (antifungal), Merck & Co | |
| enfumafungin (antifungal), Merck & Co | |

[Return to Table of Contents](#)

CHARTS



[Return to Table of Contents](#)

COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Scynexis are presented. No Consensus forecast data for R-Pharm are currently available.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

In September 2013, SCYNEXIS signed an exclusive agreement with R-Pharm to develop and commercialize SCY-078 for fungal infections in Russia, the Commonwealth of Independent States (CIS) countries and Turkey [1475286].

The drug was originally discovered through a 2002 deal which paired Merck's screening targets with SCYNEXIS's lead optimization technology, from which SCY-078 was the first clinical candidate [456447]. In May 2013, Merck returned worldwide development and commercialization rights for antifungal compound MK-3118 to SCYNEXIS [1430222].

SCY-078 CLINICAL TRIALS

Trials by Phase and Condition Studied

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|-------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Candida infection | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Fungal infection | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |

Total Trials by Phase and Status

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Total by Phase and Status | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 3 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

SCY-078 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|----------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| SCYNEXIS Inc | 2 | 0 | 0 | 0 | 2 |
| R-Pharm | 0 | 0 | 1 | 0 | 1 |
| Merck & Co Inc | 0 | 0 | 1 | 0 | 1 |

Deals by Type Chart




Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Development/Commercialization License | 1 | 0 | 1 |
| Drug - Discovery/Design | 1 | 0 | 1 |

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

| Company Name | As Owner | As Third Party | Total |
|----------------|----------|----------------|-------|
| SCYNEXIS Inc | 2 | 0 | 2 |
| Merck & Co Inc | 2 | 0 | 2 |

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship | Total |
|------------------------|-------|
| Tentative | 1 |
| Process (Intermediate) | 1 |

[Return to Table of Contents](#)

SCYX-7158

SCYX-7158 SNAPSHOT

| | |
|-----------------------------|---|
| Drug Name | SCYX-7158 |
| Key Synonyms | |
| Originator Company | SCYNEXIS Inc |
| Active Companies | SCYNEXIS Inc;Drugs for Neglected Diseases Initiative;Anacor Pharmaceuticals Inc;Pace University |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Trypanosoma cruzi infection;Trypanosoma brucei infection |
| Target-based Actions | |
| Other Actions | Unspecified drug target;Antiparasitic |
| Technologies | Oral formulation;Small molecule therapeutic |
| Last Change Date | 30-Jan-2015 |

SCYX-7158 DEVELOPMENT PROFILE

SUMMARY

SCYNEXIS, Anacor Pharmaceuticals, Pace University and the Drugs for Neglected Diseases Initiative (DNDi) are developing SCYX-7158 (AN-5568), the lead in an oxaborole series, including AN-2920, AN-3520 and SCYX-6759 (AN-4169), for the potential oral treatment of human African trypanosomiasis (HAT, sleeping sickness, Trypanosoma brucei infection) and Chagas disease (Trypanosoma cruzi infection). In February 2012, DNDi initiated a phase I trial of SCYX-7158. In January 2014, the drug was listed as being in phase I development. In December 2013, data from phase I trial was expected in the first half of 2014 and a phase II/III trial was expected to be initiated in the second half of 2014. In March 2011, Anacor was seeking to outlicense the program. In September 2014, the company was planning to conduct pivotal efficacy study.

SCYX-7158 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS


| Company | Indication | Country | Development Status | Date |
|---|------------------------------|---------|--------------------|-------------|
| Drugs for Neglected Diseases Initiative | Trypanosoma brucei infection | France | Phase 1 Clinical | 15-Feb-2012 |
| Anacor Pharmaceuticals Inc | Trypanosoma brucei infection | US | Discovery | 11-Dec-2008 |
| Anacor Pharmaceuticals Inc | Trypanosoma cruzi infection | US | Discovery | 31-Dec-2007 |
| Drugs for Neglected Diseases Initiative | Trypanosoma cruzi infection | US | Discovery | 31-Dec-2007 |
| Pace University | Trypanosoma brucei infection | US | Discovery | 11-Dec-2008 |


[Return to Table of Contents](#)




| Company | Indication | Country | Development Status | Date |
|--------------|------------------------------|---------|--------------------|-------------|
| SCYNEXIS Inc | Trypanosoma brucei infection | US | Discovery | 11-Dec-2008 |
| SCYNEXIS Inc | Trypanosoma cruzi infection | US | Discovery | 15-Aug-2010 |


SCYX-7158 CHEMICAL STRUCTURES


| CAS Registry Number: | Confidence Level: |
|---|-------------------|
| | 4 |
|  | |
| Name | Type |
| SCYX-7158 | Research Code |

| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| | 4 |
|  | |
| Name | Type |
| SCYX-6759 | Research Code |
| AN-4169 | Research Code |

[Return to Table of Contents](#)

| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 4 |
|  | |

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 3 |
|  | |

| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 3 |
|  | |

[Return to Table of Contents](#)

SCYX-7158 DRUG NAMES

| Names | Type |
|--|---------------|
| AN-4169 | Research Code |
| SCYX-7158 | Research Code |
| AN-2920 | Research Code |
| AN-3520 | Research Code |
| AN-5568 | Research Code |
| SCYX-6759 | Research Code |
| oxaborole series (human African trypanosomiasis), SCYNEXIS/DNDi/Pace University/Anacor Pharmaceuticals | |
| trypanocidal compounds, SCYNEXIS/DNDi/Pace University/Anacor Pharmaceuticals | |
| boron based antiparasitic compounds (chagas disease), Anacor Pharmaceuticals/DNDi | |

SCYX-7158 CLINICAL TRIALS

Total Trials by Phase and Status


| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Total by Phase and Status | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |

[Return to Table of Contents](#)

SCYX-7158 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drugs for Neglected Diseases Initiative | 10 | 0 | 2 | 0 | 12 |
| SCYNEXIS Inc | 2 | 0 | 0 | 0 | 2 |
| Médecins Sans Frontières | 0 | 0 | 1 | 0 | 1 |
| Swiss Agency for Development and Cooperation | 0 | 0 | 1 | 0 | 1 |
| Sanofi | 0 | 0 | 1 | 0 | 1 |
| Penn Pharmaceuticals Ltd | 0 | 0 | 1 | 0 | 1 |
| Anacor Pharmaceuticals Inc | 1 | 0 | 0 | 0 | 1 |
| Pace University | 0 | 0 | 1 | 0 | 1 |
| Advinus Therapeutics Ltd | 0 | 0 | 1 | 0 | 1 |
| Spanish Government | 0 | 0 | 1 | 0 | 1 |
| Netherlands Government | 0 | 0 | 1 | 0 | 1 |
| Bill & Melinda Gates Foundation | 0 | 0 | 1 | 0 | 1 |
| Department for International Development | 0 | 0 | 1 | 0 | 1 |
| German Government | 0 | 0 | 1 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Funding | 7 | 0 | 7 |
| Drug - Development/Commercialization License | 5 | 0 | 5 |
| Drug - Early Research/Development | 1 | 0 | 1 |

[Return to Table of Contents](#)

serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS

serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS SNAPSHOT

| | |
|----------------------|--|
| Drug Name | serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS |
| Key Synonyms | |
| Originator Company | Abide Therapeutics Inc |
| Active Companies | SCYNEXIS Inc;Abide Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Parasitic infection |
| Target-based Actions | Hydrolase inhibitor |
| Other Actions | Antiviral;Antiparasitic |
| Technologies | Small molecule therapeutic |
| Last Change Date | 15-Dec-2014 |

serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS DEVELOPMENT PROFILE

SUMMARY

Abide Therapeutics, in collaboration with SCYNEXIS, are investigating serine hydrolase inhibitors for the potential treatment of parasitic infections including malaria, leishmania and filarial worm. In December 2014, development was presumed to be ongoing.

Abide Therapeutics and SCYNEXIS, were previously investigating serine hydrolase inhibitors for the potential treatment of viral infections.

serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|------------------------|---------------------|---------|-------------------------|-------------|
| Abide Therapeutics Inc | Parasitic infection | US | Discovery | 28-Mar-2012 |
| SCYNEXIS Inc | Parasitic infection | US | Discovery | 28-Mar-2012 |
| Abide Therapeutics Inc | Viral infection | US | No Development Reported | 14-Oct-2014 |
| SCYNEXIS Inc | Viral infection | US | No Development Reported | 14-Oct-2014 |

[Return to Table of Contents](#)




serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS DRUG NAMES

| Names | Type |
|--|------|
| serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS | |

serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| SCYNEXIS Inc | 0 | 0 | 1 | 0 | 1 |
| Abide Therapeutics Inc | 1 | 0 | 0 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Drug - Discovery/Design | 1 | 0 | 1 |

[Return to Table of Contents](#)

SCY-078 (intravenous, antifungal), SCYNEXIS

SCY-078 (intravenous, antifungal), SCYNEXIS SNAPSHOT

| | |
|----------------------|--|
| Drug Name | SCY-078 (intravenous, antifungal), SCYNEXIS |
| Key Synonyms | |
| Originator Company | SCYNEXIS Inc |
| Active Companies | SCYNEXIS Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Fungal infection |
| Target-based Actions | 1,3 beta glucan synthase inhibitor |
| Other Actions | Fungicide;Glucan synthesis inhibitor |
| Technologies | Natural product;Biological therapeutic;Intravenous formulation |
| Last Change Date | 31-Mar-2015 |

SCY-078 (intravenous, antifungal), SCYNEXIS DEVELOPMENT PROFILE

SUMMARY

SCYNEXIS is investigating an intravenous formulation of SCY-078 (formerly MK-3118), an active inhibitor of glucan synthesis the lead from analogs of enfumafungin, a triterpene glycoside derived from a culture belonging to the genus *Hormonema*, as beta-(1,3) D glucan synthase inhibitors, for the potential treatment of fungal infections caused by *Candida* and *Aspergillus* species,. In March 2015, IND-enabling studies were ongoing. At that time, the company planned to initiate a phase I trial in the second half of 2015.

SCYNEXIS is also developing an oral formulation of SCY-078 for the potential treatment of fungal infections.


SCY-078 (intravenous, antifungal), SCYNEXIS DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------|------------------|---------|--------------------|-------------|
| SCYNEXIS Inc | Fungal infection | US | Discovery | 05-Jun-2013 |

SCY-078 (intravenous, antifungal), SCYNEXIS CHEMICAL STRUCTURES

[Return to Table of Contents](#)

| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| | 4 |
|  | |
| Name | Type |
| MK-3118 | Research Code |
| SCY-078 | Research Code |

SCY-078 (intravenous, antifungal), SCYNEXIS DRUG NAMES

| Names | Type |
|---|---------------|
| SCY-078 | Research Code |
| SCY-078 (intravenous, antifungal), SCYNEXIS | |
| MK-3118 | Research Code |

[Return to Table of Contents](#)

oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi

oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi SNAPSHOT

| | |
|-----------------------------|--|
| Drug Name | oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi |
| Key Synonyms | |
| Originator Company | Anacor Pharmaceuticals Inc |
| Active Companies | London School of Hygiene and Tropical Medicine;SCYNEXIS Inc;Anacor Pharmaceuticals Inc;University of Antwerp;Drugs for Neglected Diseases Initiative |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Leishmania donovani infection;Trypanosoma cruzi infection |
| Target-based Actions | |
| Other Actions | Antiparasitic;Unspecified drug target |
| Technologies | Small molecule therapeutic |
| Last Change Date | 02-Sep-2014 |

oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEVELOPMENT PROFILE

SUMMARY

Anacor Pharmaceuticals, Drugs for Neglected Diseases initiative (DNDi) and its partners SCYNEXIS, University of Antwerp and The London School of Hygiene and Tropical Medicine (LSHTM), are investigating Oxaleish (DNDi-2035804), a lead from a series of oxaboroles, for the potential treatment of visceral leishmaniasis (VL) and Chagas disease, . In March 2011, the program was listed as being in research on Anacor's pipeline; in January 2014, this was still the case. In August 2014, preclinical efficacy, pharmacokinetics, and safety profiling of the lead compound was ongoing.

oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--|-------------------------------|-------------|--------------------|-------------|
| Anacor Pharmaceuticals Inc | Leishmania donovani infection | US | Discovery | 31-Dec-2007 |
| Anacor Pharmaceuticals Inc | Trypanosoma cruzi infection | US | Discovery | 31-Dec-2007 |
| Drugs for Neglected Diseases Initiative | Leishmania donovani infection | Switzerland | Discovery | 31-Dec-2007 |
| Drugs for Neglected Diseases Initiative | Trypanosoma cruzi infection | Switzerland | Discovery | 31-Dec-2007 |
| London School of Hygiene and Tropical Medicine | Leishmania donovani infection | UK | Discovery | 31-Aug-2014 |

[Return to Table of Contents](#)



| Company | Indication | Country | Development Status | Date |
|-----------------------|-------------------------------|---------|--------------------|-------------|
| SCYNEXIS Inc | Leishmania donovani infection | US | Discovery | 31-Aug-2014 |
| University of Antwerp | Leishmania donovani infection | Belgium | Discovery | 31-Aug-2014 |


oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DRUG NAMES

| Names | Type |
|--|---------------|
| DNDi-2035804 | Research Code |
| Oxaleish | |
| oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi | |
| boron based antiparasitic compounds (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi | |

oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|---|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drugs for Neglected Diseases Initiative | 2 | 0 | 5 | 0 | 7 |
| WuXi PharmaTech (Cayman) Inc | 1 | 0 | 0 | 0 | 1 |
| Sandexis LLP | 1 | 0 | 0 | 0 | 1 |
| SCYNEXIS Inc | 0 | 0 | 1 | 0 | 1 |
| Anacor Pharmaceuticals Inc | 1 | 0 | 0 | 0 | 1 |
| University of London | 1 | 0 | 0 | 0 | 1 |
| Bill & Melinda Gates Foundation | 0 | 0 | 1 | 0 | 1 |
| University of Antwerp | 1 | 0 | 0 | 0 | 1 |

Deals by Type Chart



[Return to Table of Contents](#)

Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Early Research/Development | 3 | 0 | 3 |
| Drug - Development Services | 2 | 0 | 2 |
| Drug - Development/Commercialization License | 1 | 0 | 1 |
| Drug - Funding | 1 | 0 | 1 |

[Return to Table of Contents](#)

Oxachagas

Oxachagas SNAPSHOT

| | |
|-----------------------------|--|
| Drug Name | Oxachagas |
| Key Synonyms | |
| Originator Company | Drugs for Neglected Diseases Initiative |
| Active Companies | Drugs for Neglected Diseases Initiative;Murdoch University;SCYNEXIS Inc;University of Antwerp;Anacor Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Trypanosoma cruzi infection |
| Target-based Actions | |
| Other Actions | Unspecified drug target;Antiparasitic |
| Technologies | Small molecule therapeutic |
| Last Change Date | 03-Sep-2014 |

Oxachagas DEVELOPMENT PROFILE

SUMMARY

Drugs for Neglected Diseases Initiative in collaboration with Anacor Pharmaceuticals, SCYNEXIS, Murdoch University and University of Antwerp, is investigating Oxachagas, a program of oxaboroles, for the potential treatment of Chagas disease. By August 2014, research was underway.

Oxachagas DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|---|-----------------------------|----------------|---------------------------|-------------|
| Anacor Pharmaceuticals Inc | Trypanosoma cruzi infection | US | Discovery | 31-Aug-2014 |
| Drugs for Neglected Diseases Initiative | Trypanosoma cruzi infection | Switzerland | Discovery | 31-Aug-2014 |
| Murdoch University | Trypanosoma cruzi infection | Australia | Discovery | 31-Aug-2014 |
| SCYNEXIS Inc | Trypanosoma cruzi infection | US | Discovery | 31-Aug-2014 |
| University of Antwerp | Trypanosoma cruzi infection | Belgium | Discovery | 31-Aug-2014 |

[Return to Table of Contents](#)




Oxachagas DRUG NAMES

| Names | Type |
|--|------|
| oxaborole series (Chagas disease), DNDi/Anacor Pharmaceuticals/SCYNEXIS/Murdoch Uni/Uni of Antwerp | |
| Oxachagas | |

Oxachagas DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drugs for Neglected Diseases Initiative | 5 | 0 | 6 | 0 | 11 |
| German Government | 0 | 0 | 1 | 0 | 1 |
| WuXi PharmaTech (Cayman) Inc | 1 | 0 | 0 | 0 | 1 |
| Murdoch University | 1 | 0 | 0 | 0 | 1 |
| Sandexis LLP | 1 | 0 | 0 | 0 | 1 |
| SCYNEXIS Inc | 1 | 0 | 0 | 0 | 1 |
| Swiss Agency for Development and Cooperation | 0 | 0 | 1 | 0 | 1 |
| University of Antwerp | 1 | 0 | 0 | 0 | 1 |
| Netherlands Government | 0 | 0 | 1 | 0 | 1 |
| Department for International Development | 0 | 0 | 1 | 0 | 1 |
| Anacor Pharmaceuticals Inc | 1 | 0 | 0 | 0 | 1 |
| Spanish Government | 0 | 0 | 1 | 0 | 1 |

Deals by Type Chart



[Return to Table of Contents](#)

Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Funding | 5 | 0 | 5 |
| Drug - Development Services | 2 | 0 | 2 |
| Drug - Development/Commercialization License | 2 | 0 | 2 |
| Drug - Early Research/Development | 1 | 0 | 1 |
| Drug - Screening/Evaluation | 1 | 0 | 1 |

[Return to Table of Contents](#)

ciclosporin analogs (fungal infection), SCYNEXIS

ciclosporin analogs (fungal infection), SCYNEXIS SNAPSHOT

| | |
|----------------------|--|
| Drug Name | ciclosporin analogs (fungal infection), SCYNEXIS |
| Key Synonyms | |
| Originator Company | SCYNEXIS Inc |
| Active Companies | SCYNEXIS Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Fungal infection |
| Target-based Actions | |
| Other Actions | Fungicide;Unspecified drug target |
| Technologies | Biological therapeutic;Peptide |
| Last Change Date | 17-Feb-2015 |

ciclosporin analogs (fungal infection), SCYNEXIS DEVELOPMENT PROFILE

SUMMARY

SCYNEXIS is investigating a program of non-immunosuppressive ciclosporin analogs, for the potential treatment of fungal infections. In October 2014, the program was listed as being in preclinical development.

ciclosporin analogs (fungal infection), SCYNEXIS DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------|------------------|---------|--------------------|-------------|
| SCYNEXIS Inc | Fungal infection | US | Discovery | 14-Oct-2014 |


ciclosporin analogs (fungal infection), SCYNEXIS DRUG NAMES

| Names | Type |
|--|------|
| antifungal therapeutics, SCYNEXIS | |
| ciclosporin analogs (fungal infection), SCYNEXIS | |

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|---------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| US Government | 0 | 0 | 1 | 0 | 1 |
| SCYNEXIS Inc | 1 | 0 | 0 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type | Active | Inactive | Total |
|----------------|--------|----------|-------|
| Drug - Funding | 1 | 0 | 1 |

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS SNAPSHOT

| | |
|-----------------------------|--|
| Drug Name | oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS |
| Key Synonyms | |
| Originator Company | Drugs for Neglected Diseases Initiative |
| Active Companies | Anacor Pharmaceuticals Inc;Drugs for Neglected Diseases Initiative;Pace University;SCYNEXIS Inc |
| Inactive Companies | |
| Highest Status | Suspended |
| Active Indications | Trypanosoma brucei infection |
| Target-based Actions | |
| Other Actions | Unspecified drug target;Antiparasitic |
| Technologies | Small molecule therapeutic |
| Last Change Date | 05-Sep-2014 |

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEVELOPMENT PROFILE

SUMMARY

Drugs for Neglected Diseases initiative (DNDi), SCYNEXIS, Anacor and Pace University were investigating SCYX-1608210 and SCYX-1330682 as backup compounds of SCYX-7158, an oxaborole, for the potential treatment of human African trypanosomiasis (HAT),. In April 2007, development was ongoing ; in August 2012, the program was listed as being under preclinical development. In January 2014, the program was listed as being under research. However, by September 2014, further development of both compounds was suspended; due to limited resources, DNDi would focus on the development of SCYX-7158 and fexinidazole and would only re-open the program if SCYX-7158 did not prove to be successful in clinical trials.

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|---|------------------------------|-------------|--------------------|-------------|
| Anacor Pharmaceuticals Inc | Trypanosoma brucei infection | US | Suspended | 03-Sep-2014 |
| Drugs for Neglected Diseases Initiative | Trypanosoma brucei infection | Switzerland | Suspended | 03-Sep-2014 |
| Pace University | Trypanosoma brucei infection | US | Suspended | 03-Sep-2014 |
| SCYNEXIS Inc | Trypanosoma brucei infection | US | Suspended | 03-Sep-2014 |

[Return to Table of Contents](#)




oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DRUG NAMES

| Names | Type |
|--|---------------|
| SCYX-1608210 | Research Code |
| backup compounds of SCYX-7158 (HAT), DNDi/Anacor/Pace University/SCYNEXIS | |
| oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS | |
| SCYX-1330682 | Research Code |

oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drugs for Neglected Diseases Initiative | 4 | 0 | 4 | 0 | 8 |
| Department for International Development | 0 | 0 | 1 | 0 | 1 |
| Médecins Sans Frontières | 0 | 0 | 1 | 0 | 1 |
| Anacor Pharmaceuticals Inc | 1 | 0 | 0 | 0 | 1 |
| WuXi PharmaTech (Cayman) Inc | 1 | 0 | 0 | 0 | 1 |
| Pace University | 1 | 0 | 0 | 0 | 1 |
| Swiss Agency for Development and Cooperation | 0 | 0 | 1 | 0 | 1 |
| SCYNEXIS Inc | 1 | 0 | 0 | 0 | 1 |
| Spanish Government | 0 | 0 | 1 | 0 | 1 |

Deals by Type Chart



[Return to Table of Contents](#)

Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Funding | 4 | 0 | 4 |
| Drug - Development/Commercialization License | 3 | 0 | 3 |
| Drug - Development Services | 1 | 0 | 1 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

